Foghorn Therapeutics Inc.

NASDAQ:FHTX

Biotechnology

Healthcare
$1.83 +2.35%

+$0.10 today

Market cap
$109.73M
Beta
2.89
P/E (TTM)
-3.8
EPS (TTM)
-$1.08
52W Low $3.27High $6.95

Volume 1.76M

Average 0.15M

Returns on capital

Foghorn Therapeutics Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

68.5%

avg -12107.0%

ROIC

-58.9%

avg -79.3%

ROA

-37.5%

avg -58.2%

Analysis

ROE is currently the strongest return metric at 68.5% versus its period average of -12107.0%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Adrian H. Gottschalk

President, Chief Executive Officer & DirectorUSD 1.03M50——

Steven F. Bellon

Chief Scientific OfficerUSD 730.2K61300.00K0.51%

Alfonso Quintas Cardama

Chief Medical OfficerUSD 714.36K55300.00K0.51%

Ryan D. Maynard

Chief Financial OfficerUSD 637.81K570<0.01%

Michael J. LaCascia

Chief Legal OfficerUSD 565.5K61——

Douglas G. Cole

Founder & Independent Chairman of the BoardUSD 85.35K6628.00K0.05%

Saurabh Sewak

Vice President of Corporate Development————

Karin Hellsvik

Chief of Staff to the CEO, VP, Head of Corporate Affairs, Investor Relations & Operations————

Carlos Costa

Chief People Officer—53230.00K0.39%

Gerald R. Crabtree

Founder & Member of Scientific Advisory Board————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 24, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+17.1%
+21.4% (5yr)3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Recent growth has been strongest in Revenue at +17.1% over three years. Forward estimates point to Revenue at +21.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Foghorn Therapeutics Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about FHTX's management, answered from reported figures.

Who manages FHTX?

Foghorn Therapeutics Inc. (FHTX) lists 10 active executives. The top listed executive is Douglas G. Cole, Founder & Independent Chairman of the Board.

Are FHTX insiders buying or selling?

Recent insider activity shows net buying of $85.32M.